HC Wainwright reissued their buy rating on shares of Humacyte (NASDAQ:HUMA - Free Report) in a report released on Wednesday morning,Benzinga reports. They currently have a $12.00 price objective on the stock.
Several other equities research analysts have also recently issued reports on the company. Piper Sandler set a $6.00 target price on Humacyte and gave the stock a "neutral" rating in a report on Friday, October 18th. EF Hutton Acquisition Co. I raised Humacyte to a "strong-buy" rating in a report on Monday, September 9th. TD Cowen reissued a "buy" rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Benchmark reissued a "buy" rating and set a $15.00 price objective on shares of Humacyte in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Humacyte presently has a consensus rating of "Buy" and an average price target of $11.00.
Get Our Latest Stock Analysis on HUMA
Humacyte Stock Performance
Shares of Humacyte stock traded down $0.10 during trading hours on Wednesday, hitting $5.26. The company's stock had a trading volume of 1,293,670 shares, compared to its average volume of 2,363,510. Humacyte has a 12-month low of $2.25 and a 12-month high of $9.97. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 5.41. The business has a 50 day moving average price of $5.45 and a two-hundred day moving average price of $6.18.
Humacyte (NASDAQ:HUMA - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). As a group, equities analysts forecast that Humacyte will post -1.18 EPS for the current fiscal year.
Insider Activity
In related news, Director Brady W. Dougan sold 252,676 shares of the business's stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total value of $1,695,455.96. Following the completion of the sale, the director now owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Laura E. Niklason sold 157,704 shares of the company's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $5.42, for a total value of $854,755.68. Following the transaction, the chief executive officer now directly owns 3,519,558 shares of the company's stock, valued at $19,076,004.36. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total value of $1,695,455.96. Following the sale, the director now directly owns 4,306,464 shares in the company, valued at $28,896,373.44. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,084,153 shares of company stock valued at $6,869,996. 11.20% of the stock is currently owned by insiders.
Institutional Trading of Humacyte
Institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new position in Humacyte in the second quarter valued at about $28,000. Concurrent Investment Advisors LLC purchased a new position in Humacyte in the third quarter valued at about $75,000. Principal Financial Group Inc. purchased a new position in Humacyte in the second quarter valued at about $83,000. Profund Advisors LLC purchased a new position in Humacyte in the second quarter valued at about $97,000. Finally, XTX Topco Ltd acquired a new stake in shares of Humacyte in the second quarter valued at approximately $110,000. Institutional investors and hedge funds own 44.71% of the company's stock.
Humacyte Company Profile
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
